HER2 sequence in gastric cancer: zanidatamab/trastuzumab + chemo ± PD-1 → T-DXd
For HER2-positive stomach cancer, an antibody-plus-chemotherapy first, then Enhertu when it progresses. Both steps now have phase 3 proof.
First line: trastuzumab + chemotherapy + pembrolizumab (KEYNOTE-811, PD-L1 CPS ≥1) or zanidatamab + chemotherapy ± tislelizumab (HERIZON-GEA-01, PFS 12.4 vs 8.1 months). Second line: T-DXd (DESTINY-Gastric04, OS 14.7 vs 11.4 months). HER2 loss after first-line therapy occurs in ~30%, so re-biopsy or ctDNA before T-DXd is advisable.
Pages like this
not linked directly; found by shared links- PersonKohei Shitara
Shares ToGA, DESTINY-Gastric04, Trastuzumab deruxtecan, HER2.
- PersonYung-Jue Bang
Shares ToGA, Trastuzumab, HER2, Gastric & gastro-oesophageal junction cancer.
- IdeaBiomarker-directed first-line quadruplets in gastric cancer
Shares HERIZON-GEA-01, Zanidatamab, HER2, Gastric & gastro-oesophageal junction cancer.
- TermEpitope
Shares Zanidatamab, Trastuzumab, HER2.
- PersonYelena Y. Janjigian
Shares Trastuzumab, HER2, Pembrolizumab, Gastric & gastro-oesophageal junction cancer.
- PersonJeeyun Lee
Shares Zanidatamab, HER2, Gastric & gastro-oesophageal junction cancer.
- TrialHERIZON-BTC-302
Shares Zanidatamab, HER2.
- IdeaHER2 ADCs as standard for HER2-positive serous endometrial cancer
Shares Trastuzumab, Trastuzumab deruxtecan, HER2.